Integral DiagnosticsITGDF 72 Return-on-Tangible-Asset is 3.19% as of Dec. 2025, which is 71% below its 10-year median of 11.18. GuruFocus rates ITGDF with a GF Score™ of 72/100 and a GF Value™ of $1.17 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 63.38% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Integral Diagnostics's annualizedNet Income for the quarter that ended in Dec. 2025 was $11.9 Mil. Integral Diagnostics's average total tangible assets for the quarter that ended in Dec. 2025 was $373.1 Mil. Therefore, Integral Diagnostics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 3.19%.
The historical rank and industry rank for Integral Diagnostics's Return-on-Tangible-Asset or its related term are showing as below:
ITGDF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -17.11 Med: 11.18 Max: 21.02
Current: 2.58
During the past 10 years, Integral Diagnostics's highest Return-on-Tangible-Asset was 21.02%. The lowest was -17.11%. And the median was 11.18%.
ITGDF's Return-on-Tangible-Asset is ranked better than 63.38% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.25
vs ITGDF: 2.58
Integral Diagnostics (OTCPK:ITGDF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Integral Diagnostics Return-on-Tangible-Asset Related Terms
Integral Diagnostics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics Return-on-Tangible-Asset Chart
ITGDF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 3.19% mean?
Integral Diagnostics (ITGDF) has a Return-on-Tangible-Asset of 3.19% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Integral Diagnostics and its competitors. This is 71% below median its historical median of 11.18. According to the industry distribution chart, Integral Diagnostics ranks #78 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 36.6%.
Is Integral Diagnostics' Return-on-Tangible-Asset too high?
Integral Diagnostics' current Return-on-Tangible-Asset of 3.19% is 71% below median its 10-year median of 11.18. Based on the distribution chart, Integral Diagnostics ranks #78 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #78 out of 213 companies for Return-on-Tangible-Asset. This puts Integral Diagnostics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Integral Diagnostics and its competitors. Integral Diagnostics's current Return-on-Tangible-Asset is 3.19%, which is 71% below median its own 10-year median of 11.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $2.61 — trading 123.3% above its estimated fair value. The current Return-on-Tangible-Asset is 3.19%, which is 71% below median its 10-year median of 11.18. Integral Diagnostics' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current Return-on-Tangible-Asset is 3.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be overvalued.
The current stock price of $2.61 is trading 123.3% above its estimated GF Value™ of $1.17.
GuruFocus considers Integral Diagnostics to be Significantly Overvalued.
Key valuation signals for ITGDF:
Return-on-Tangible-Asset: 3.19% (71% below median its 10-year median of 11.18)
GF Value™: $1.17 vs. price of $2.61 (123.3% above fair value)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
72GF Score
Get the complete analysis for ITGDF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 
